Amgen (AMGN) VP Finance receives 938-share stock grant and dividend equivalents

Rhea-AI Filing Summary

Amgen Inc. reported that VP, Finance & CAO Matthew C. Busch acquired 938 shares of common stock on March 3, 2026 through a grant or award, at a stated price of $0.00 per share. After this equity award, his directly held common stock position increased to 4,361 shares.

The reported holdings include 60 dividend equivalents (DEs) granted under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These DEs are credited to Busch’s unvested restricted stock units and will be paid out in Amgen common shares on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Busch Matthew C.

Role VP, Finance & CAO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	938	$0.00	--

Holdings After Transaction: Common Stock — 4,361 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Busch Matthew C.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Finance & CAO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		938	A	$0	4,361(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Matthew C. Busch	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Amgen (AMGN) report for Matthew C. Busch?

Amgen reported that VP, Finance & CAO Matthew C. Busch received an equity award of 938 shares of common stock on March 3, 2026. The transaction was coded as a grant or other acquisition, not an open-market purchase or sale, and increased his direct holdings.

How many Amgen (AMGN) shares does Matthew C. Busch hold after this grant?

Following the March 3, 2026 equity award, Matthew C. Busch directly holds 4,361 shares of Amgen common stock. This total includes shares received via the 938-share grant reported in the filing, reflecting his updated direct ownership position as an Amgen senior finance executive.

Was cash paid for the Amgen (AMGN) shares granted to Matthew C. Busch?

The 938 Amgen shares granted to Matthew C. Busch carried a reported price of $0.00 per share, indicating an award rather than a cash purchase. This aligns with typical equity incentive grants provided to executives as part of long-term compensation programs at large public companies.

What are the 60 dividend equivalents (DEs) referenced in the Amgen (AMGN) Form 4?

The filing states that Busch’s holdings include 60 dividend equivalents granted under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These DEs are credited to his unvested RSUs and will convert into Amgen common shares on a one-to-one basis as the RSUs vest.

How will the dividend equivalents for Matthew C. Busch’s Amgen (AMGN) RSUs be settled?

According to the footnote, dividend equivalents tied to Busch’s unvested RSUs will be paid out in Amgen common stock on a one-to-one basis when the RSUs vest. Any remaining fractional share amount will be settled through a cash payment at that time.

Under which plan were Matthew C. Busch’s Amgen (AMGN) dividend equivalents granted?

The 60 dividend equivalents in Busch’s reported holdings were granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. They are subject to a qualifying dividend reinvestment plan and are linked to his unvested restricted stock units in Amgen common stock.